| Autor: |
Mullol J; Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain., Backer V; Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark., Constantinidis J; Department of ORL, AHEPA University Hospital, Thessaloniki, Greece., Eguíluz-Gracia I; Allergy Unit, Hospital Regional Universitario de Málaga. Allergy group, IBIMA-Plataforma BIONAND. RICORS Inflammatory Diseases. Málaga, Spain., Moure AL; Specialty Care Unit, Medical Affairs, GSK, Madrid, Spain., Cuervo-Pinto R; Specialty Care Unit, Medical Affairs, GSK, Madrid, Spain., Zhang L; Respiratory Biostatistics, GSK, Warren, NJ, USA., Shah P; Data Analysis Statistics, GSK, UK., Kerr W; Global Specialty Care, GSK, UK., Hellings P; Otorhinolaryngology, Catholic University of Leuven, and Upper Airways Research Laboratory, University of Ghent, Belgium. |
| Abstrakt: |
Chronic rhinosinusitis with nasal polyps (CRSwNP) often co-exists with asthma and non-steroidal anti-inflammatory drug- exacerbated respiratory disease (N-ERD), creating a more severe phenotype and an additional burden compared with CRSwNP disease alone (1-3). The relationship between these diseases in terms of shared immunological disbalance has been coined in the literature as 'global airway disease' or 'unified airway disease' and requires integrated treatment strategies (4-6). Our post hoc analysis of the Phase III randomised, double-blind, placebo-controlled, multicentre SYNAPSE study (GSK ID: 205687; NCT03085797 (7)) assessed the efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, in simultaneously improving both CRSwNP and asthma outcomes versus placebo. By utilising a combined measure that accounts for quality of life, sinonasal symptoms and asthma control, we aimed to validate the potential of mepolizumab as an effective therapeutic option for global airway disease. |
